Clinical Trials Browser

Phase 1/2 × Recruiting × enzalutamide × Clear all

Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant

NCT07226986 2026-05-11

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

NCT06616155 2026-05-05

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Recruiting

20 enrolled

Genitourinary

Prostatic Neoplasms

NCT06457919 2026-03-24

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

Phase 1/2 Recruiting

50 enrolled

Genitourinary

Prostatic Neoplasms

NCT02861573 2026-02-17

KEYNOTE-365

Phase 1/2 Recruiting

1,200 enrolled

Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT06236139 2026-02-17

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Recruiting

48 enrolled

Genitourinary

Prostatic Neoplasms

NCT06126731 2025-11-24

Combination Study of Antibiotics With Enzalutamide (PROMIZE)

Phase 1/2 Recruiting

39 enrolled

Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT05914116 2025-11-21

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Phase 1/2 Recruiting

862 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT04104776 2025-05-15

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Phase 1/2 Recruiting

275 enrolled

GenitourinaryGynecologicLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Endometrial Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT06702995 2025-04-20

Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Recruiting

307 enrolled

Genitourinary

Metastatic Castrate-Resistant Prostate Cancer

Clinical Trials

IDeate-Prostate02

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

KEYNOTE-365

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Combination Study of Antibiotics With Enzalutamide (PROMIZE)

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer